肝癌早筛：从LDT到IVD，稳步推进商业模式转型 头豹词条报告系列

Investment Rating - The report does not explicitly state an investment rating for the liver cancer early screening industry Core Insights - The liver cancer early screening industry aims to improve cure rates and patient survival quality through early detection. The market is rapidly growing due to the release of liver cancer diagnosis guidelines and the emergence of liquid biopsy technologies. By 2030, the price for a single test is expected to drop below 1,000 yuan [5][34][39] Industry Definition - Liver cancer early screening refers to the use of various medical testing technologies to identify individuals at high risk of liver cancer from asymptomatic or mildly symptomatic populations for early diagnosis and treatment [6] Industry Classification - The liver cancer early screening industry is classified into four categories based on detection technology: serum biomarker detection, liquid biopsy, imaging diagnosis enhancement, and comprehensive multi-modal analysis [7][11] Industry Characteristics - The industry is characterized by a phase of commercial model innovation, high technological innovation capability, and a significant demand for interdisciplinary and practical talent [12][14] Development History - The liver cancer screening initiative in China began in 2006 and has evolved through various phases, with significant advancements in liquid biopsy technology and the establishment of clinical guidelines [15][17][31] Industry Chain Analysis - The upstream of the liver cancer early screening industry consists of gene sequencing instrument and reagent suppliers, while the midstream includes service providers that develop early screening products and services [18][19] Market Demand - There is a substantial demand for liver cancer early screening, with approximately 107 million individuals in China at high risk, including 7 million cirrhosis patients and 90 million HBV carriers [21][31] Market Size - The market size of the liver cancer early screening industry grew from 52 million yuan in 2018 to 14.821 billion yuan in 2023, with a compound annual growth rate of 209.64%. It is projected to reach 48.26 billion yuan by 2028 [34][35] Future Trends - The report anticipates that as public health awareness increases and technology matures, the penetration rate of liver cancer early screening will rise, potentially reaching over 10% by 2030 [38]